Dr Reddys Laboratories (RDY) Net Cash Flow (2024 - 2025)

Dr Reddys Laboratories (RDY) recorded quarterly Net Cash Flow of $8.1 million in Q3 2025, up 112.03% quarter-over-quarter from -$67.4 million in Q2 2025, and down 89.38% on a YoY basis from $76.4 million in Q3 2024.

Dr Reddys Laboratories (RDY) Net Cash Flow (2024 - 2025) Analysis & Trends

Dr Reddys Laboratories' Net Cash Flow history runs 2 years deep, the most recent figure standing at $8.1 million for Q3 2025.

  • In Q3 2025, Net Cash Flow fell 89.38% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at -$59.3 million (down 218.9% YoY), while the FY2026 annual figure was $139.0 million, down 56.43% from the prior year.
  • Net Cash Flow was $8.1 million for Q3 2025 at Dr Reddys Laboratories, up from -$67.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $76.4 million in Q3 2024 to a low of -$67.4 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 202.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -526.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -277.40 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -446.50 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -112.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -768.22 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -3.97 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 139.49 Mn
10 Dr Reddys Laboratories 122.03 Mn -51.98 Mn 368.55 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 8.11 Mn
Sep 30, 2025 8.11 Mn
Jun 30, 2025 -67.37 Mn
Jun 30, 2025 -67.37 Mn
Sep 30, 2024 76.35 Mn
Sep 30, 2024 76.35 Mn
Jun 30, 2024 -26.50 Mn
Jun 30, 2024 -26.50 Mn